Prospective Validation of the LCrossed D sign©mann Index in Children: A Report from the Multicentre Image Kids Study

Gili Focht; Ruth Cytter Kuint; Mary Louise C. Greer; Li Tal Pratt; Denise A. Castro; Peter C. Church; Víctor Manuel Navas-López; Robert N. Baldassano; Joachim Høg Mortensen; Florian Rieder; Baruch Yerushalmi; Anat Ilivitzki; Osnat Konen; Anne M. Griffiths; Dan Turner

doi:10.1093/ecco-jcc/jjad017

Prospective Validation of the LCrossed D sign©mann Index in Children: A Report from the Multicentre Image Kids Study

Gili Focht, Ruth Cytter Kuint, Mary Louise C. Greer, Li Tal Pratt, Denise A. Castro, Peter C. Church, Víctor Manuel Navas-López, Robert N. Baldassano, Joachim Høg Mortensen, Florian Rieder, Baruch Yerushalmi, Anat Ilivitzki, Osnat Konen, Anne M. Griffiths, Dan Turner^*

^*Corresponding author for this work

Faculty of Medicine

Research output: Contribution to journal › Article › peer-review

1 Scopus citations

Abstract

Background:

Original language	American English
Pages (from-to)	943-949
Number of pages	7
Journal	Journal of Crohn's and Colitis
Volume	17
Issue number	6
DOIs	https://doi.org/10.1093/ecco-jcc/jjad017
State	Published - 1 Jun 2023

Bibliographical note

Funding Information:
GF—received in the past 3 years consultancy fees from Abbvie and Lilly. RCK—received in the past 3 years consultancy fees from Alnylam. MLG—received in the past 3 years an AbbVie investigator-initiated research grant and honoraria, Samsung honoraria. LP, DAC, RNB, BY, AI, OK—None. PC—received in the past 3 years speaker fees, consultancy fees or grants from Abbvie, Amgen, Janssen, Takeda and Viatris. VMNL—received in past 3 years speaker fees, consultancy fees or grants from Abbvie, Rb, Nestle Health Science, Ordesa, Lactalis and Adacyte Therapeutics. JHM—None. FR—received in past 3 years consultancy fees from Adnovate, Agomab, Allergan, AbbVie, Arena, Boehringer-Ingelheim, Celgene/BMS, CDISC, Celsius, Cowen, Ferring, Galapagos, Galmed, Genentech, Gilead, Gossamer, Guidepoint, Helmsley, Horizon Therapeutics, Image Analysis Limited, Index Pharma, Jannsen, Koutif, Mestag, Metacrine, Mopac, Morphic, Organovo, Origo, Pfizer, Pliant, Prometheus Biosciences, Receptos, RedX, Roche, Samsung, Surmodics, Surrozen, Takeda, Techlab, Theravance, Thetis, UCB, Ysios and 89Bio. AMG—received in the past 3 years consultancy fees from Abbvie, Amgen, Bristol Myers Squibb, Lilly, Janssen, Merck, Pfizer, Takeda; speaker fees from Abbvie, Janssen; investigator-initiated research grant from Abbvie. DT—received in the past 3 years consultancy fees, research grant, royalties or honorarium from Janssen, Pfizer, Hospital for Sick Children, Ferring, Abbvie, Takeda, Atlantic Health, Shire, Celgene, Lilly, Roche, ThermoFisher, BMS. Acknowledgments

Funding Information:
The ImageKids study was supported by an educational grant from AbbVie (grant number IMM-11-0077), which was not involved in any part of the study including protocol preparation, data acquisition, analyses or manuscript preparation.

Publisher Copyright:
© 2023 Oxford University Press. All rights reserved.

Keywords

Crohn's disease
Lemann score
MRE
Paediatrics

Access to Document

10.1093/ecco-jcc/jjad017

Cite this

Focht, G., Kuint, R. C., Greer, M. L. C., Pratt, L. T., Castro, D. A., Church, P. C., Navas-López, V. M., Baldassano, R. N., Mortensen, J. H., Rieder, F., Yerushalmi, B., Ilivitzki, A., Konen, O., Griffiths, A. M., & Turner, D. (2023). Prospective Validation of the LCrossed D sign©mann Index in Children: A Report from the Multicentre Image Kids Study. Journal of Crohn's and Colitis, 17(6), 943-949. https://doi.org/10.1093/ecco-jcc/jjad017

@article{e3414b277f7344eea0aea609e20287dc,

title = "Prospective Validation of the LCrossed D sign{\textcopyright}mann Index in Children: A Report from the Multicentre Image Kids Study",

abstract = "Background:",

keywords = "Crohn's disease, Lemann score, MRE, Paediatrics",

author = "Gili Focht and Kuint, {Ruth Cytter} and Greer, {Mary Louise C.} and Pratt, {Li Tal} and Castro, {Denise A.} and Church, {Peter C.} and Navas-L{\'o}pez, {V{\'i}ctor Manuel} and Baldassano, {Robert N.} and Mortensen, {Joachim H{\o}g} and Florian Rieder and Baruch Yerushalmi and Anat Ilivitzki and Osnat Konen and Griffiths, {Anne M.} and Dan Turner",

note = "Funding Information: GF—received in the past 3 years consultancy fees from Abbvie and Lilly. RCK—received in the past 3 years consultancy fees from Alnylam. MLG—received in the past 3 years an AbbVie investigator-initiated research grant and honoraria, Samsung honoraria. LP, DAC, RNB, BY, AI, OK—None. PC—received in the past 3 years speaker fees, consultancy fees or grants from Abbvie, Amgen, Janssen, Takeda and Viatris. VMNL—received in past 3 years speaker fees, consultancy fees or grants from Abbvie, Rb, Nestle Health Science, Ordesa, Lactalis and Adacyte Therapeutics. JHM—None. FR—received in past 3 years consultancy fees from Adnovate, Agomab, Allergan, AbbVie, Arena, Boehringer-Ingelheim, Celgene/BMS, CDISC, Celsius, Cowen, Ferring, Galapagos, Galmed, Genentech, Gilead, Gossamer, Guidepoint, Helmsley, Horizon Therapeutics, Image Analysis Limited, Index Pharma, Jannsen, Koutif, Mestag, Metacrine, Mopac, Morphic, Organovo, Origo, Pfizer, Pliant, Prometheus Biosciences, Receptos, RedX, Roche, Samsung, Surmodics, Surrozen, Takeda, Techlab, Theravance, Thetis, UCB, Ysios and 89Bio. AMG—received in the past 3 years consultancy fees from Abbvie, Amgen, Bristol Myers Squibb, Lilly, Janssen, Merck, Pfizer, Takeda; speaker fees from Abbvie, Janssen; investigator-initiated research grant from Abbvie. DT—received in the past 3 years consultancy fees, research grant, royalties or honorarium from Janssen, Pfizer, Hospital for Sick Children, Ferring, Abbvie, Takeda, Atlantic Health, Shire, Celgene, Lilly, Roche, ThermoFisher, BMS. Acknowledgments Funding Information: The ImageKids study was supported by an educational grant from AbbVie (grant number IMM-11-0077), which was not involved in any part of the study including protocol preparation, data acquisition, analyses or manuscript preparation. Publisher Copyright: {\textcopyright} 2023 Oxford University Press. All rights reserved.",

year = "2023",

month = jun,

day = "1",

doi = "10.1093/ecco-jcc/jjad017",

language = "American English",

volume = "17",

pages = "943--949",

journal = "Journal of Crohn's and Colitis",

issn = "1873-9946",

publisher = "Oxford University Press",

number = "6",

}

Focht, G, Kuint, RC, Greer, MLC, Pratt, LT, Castro, DA, Church, PC, Navas-López, VM, Baldassano, RN, Mortensen, JH, Rieder, F, Yerushalmi, B, Ilivitzki, A, Konen, O, Griffiths, AM & Turner, D 2023, 'Prospective Validation of the LCrossed D sign©mann Index in Children: A Report from the Multicentre Image Kids Study', Journal of Crohn's and Colitis, vol. 17, no. 6, pp. 943-949. https://doi.org/10.1093/ecco-jcc/jjad017

TY - JOUR

T1 - Prospective Validation of the LCrossed D sign©mann Index in Children

T2 - A Report from the Multicentre Image Kids Study

AU - Focht, Gili

AU - Kuint, Ruth Cytter

AU - Greer, Mary Louise C.

AU - Pratt, Li Tal

AU - Castro, Denise A.

AU - Church, Peter C.

AU - Navas-López, Víctor Manuel

AU - Baldassano, Robert N.

AU - Mortensen, Joachim Høg

AU - Rieder, Florian

AU - Yerushalmi, Baruch

AU - Ilivitzki, Anat

AU - Konen, Osnat

AU - Griffiths, Anne M.

AU - Turner, Dan

N1 - Funding Information: GF—received in the past 3 years consultancy fees from Abbvie and Lilly. RCK—received in the past 3 years consultancy fees from Alnylam. MLG—received in the past 3 years an AbbVie investigator-initiated research grant and honoraria, Samsung honoraria. LP, DAC, RNB, BY, AI, OK—None. PC—received in the past 3 years speaker fees, consultancy fees or grants from Abbvie, Amgen, Janssen, Takeda and Viatris. VMNL—received in past 3 years speaker fees, consultancy fees or grants from Abbvie, Rb, Nestle Health Science, Ordesa, Lactalis and Adacyte Therapeutics. JHM—None. FR—received in past 3 years consultancy fees from Adnovate, Agomab, Allergan, AbbVie, Arena, Boehringer-Ingelheim, Celgene/BMS, CDISC, Celsius, Cowen, Ferring, Galapagos, Galmed, Genentech, Gilead, Gossamer, Guidepoint, Helmsley, Horizon Therapeutics, Image Analysis Limited, Index Pharma, Jannsen, Koutif, Mestag, Metacrine, Mopac, Morphic, Organovo, Origo, Pfizer, Pliant, Prometheus Biosciences, Receptos, RedX, Roche, Samsung, Surmodics, Surrozen, Takeda, Techlab, Theravance, Thetis, UCB, Ysios and 89Bio. AMG—received in the past 3 years consultancy fees from Abbvie, Amgen, Bristol Myers Squibb, Lilly, Janssen, Merck, Pfizer, Takeda; speaker fees from Abbvie, Janssen; investigator-initiated research grant from Abbvie. DT—received in the past 3 years consultancy fees, research grant, royalties or honorarium from Janssen, Pfizer, Hospital for Sick Children, Ferring, Abbvie, Takeda, Atlantic Health, Shire, Celgene, Lilly, Roche, ThermoFisher, BMS. Acknowledgments Funding Information: The ImageKids study was supported by an educational grant from AbbVie (grant number IMM-11-0077), which was not involved in any part of the study including protocol preparation, data acquisition, analyses or manuscript preparation. Publisher Copyright: © 2023 Oxford University Press. All rights reserved.

PY - 2023/6/1

Y1 - 2023/6/1

N2 - Background:

AB - Background:

KW - Crohn's disease

KW - Lemann score

KW - MRE

KW - Paediatrics

UR - http://www.scopus.com/inward/record.url?scp=85163175448&partnerID=8YFLogxK

U2 - 10.1093/ecco-jcc/jjad017

DO - 10.1093/ecco-jcc/jjad017

M3 - Article

C2 - 36756849

AN - SCOPUS:85163175448

SN - 1873-9946

VL - 17

SP - 943

EP - 949

JO - Journal of Crohn's and Colitis

JF - Journal of Crohn's and Colitis

IS - 6

ER -

Prospective Validation of the LCrossed D sign©mann Index in Children: A Report from the Multicentre Image Kids Study

Abstract

Bibliographical note

Keywords

Access to Document

Other files and links

Fingerprint

Cite this